US Patent 11,752,137: Lotilaner Ophthalmic Composition Claims, Scope, and Patent Landscape

US Patent 11,752,137 protects sterile lotilaner eye-drop compositions containing approximately 0.10% to 0.50% lotilaner, with dependent claims covering preservatives, hydrogenated castor oil, specific concentrations, dosing schedules, administration volumes, and treatment of ocular Demodex-related disorders. The commercial product most closely associated with the claims is XDEMVY, lotilaner ophthalmic solution 0.25%, marketed by Tarsus Pharmaceuticals for Demodex blepharitis.

The strongest claim coverage is concentrated in three areas:

The formulation itself, particularly 0.25% lotilaner eye drops with hydrogenated castor oil.
Repeated topical administration, including twice-daily dosing for six weeks.
Use in ocular Demodex infestation and associated conditions such as blepharitis, ocular rosacea, meibomian gland dysfunction and dry eye disease.

What does US Patent 11,752,137 cover?

The patent claims an ophthalmic composition containing lotilaner as the active pharmaceutical ingredient in a sterile, nonirritating eye-drop vehicle. Claim 1 establishes the principal composition scope:

Claim element	Required limitation
Active ingredient	Lotilaner
Dosage form	Eye drop
Vehicle	Pharmaceutically acceptable vehicle
Sterility	Composition must be sterile
Tolerability	Composition must be nonirritating to the eye
Concentration	About 0.10% to about 0.50% by weight

A competing product must satisfy every limitation of an asserted claim for literal infringement. A product containing lotilaner outside the claimed concentration range, or delivered in a form other than an eye drop, would present a different literal infringement analysis. The doctrine of equivalents could still be relevant, but its application would depend on prosecution history, claim amendments and the technical differences between products.

The patent does not claim every possible lotilaner product. Its central scope is limited to ophthalmic delivery in the claimed concentration range and to the specified quality and formulation characteristics.

How are the claims organized?

Claims 1 through 8: formulation and composition claims

Claims 1 through 8 create a layered formulation estate.

Claim	Principal subject matter
1	Sterile, nonirritating lotilaner eye drop containing 0.10%-0.50% lotilaner
2	Claim 1 composition containing a preservative
3	Lotilaner is the sole active ingredient
4	Composition excludes tea tree oil
5	Composition contains castor oil
6	Castor oil is hydrogenated castor oil
7	Lotilaner concentration is approximately 0.15%-0.40%
8	Approximately 0.25% lotilaner with hydrogenated castor oil

Claim 1 is the broadest composition claim. Claim 8 is narrower but commercially important because it aligns closely with the approved XDEMVY concentration and formulation approach.

Claims 9 through 13: dosing and administration claims

These claims extend protection beyond the bottle formulation to the intended treatment regimen.

Claim	Dosing limitation
9	At least once daily for at least four weeks
10	At least twice daily for at least four weeks
11	At least twice daily for at least six weeks
12	25-50 microliters at least once daily
13	25-50 microliters at least twice daily for at least six weeks

Claim 13 is particularly aligned with the approved XDEMVY regimen. The FDA prescribing information directs administration of one drop in each affected eye twice daily for six weeks. The package design and dosage instructions therefore may be relevant to infringement analysis where a competing product uses the same concentration and dosing schedule.[1]

Claims 14 through 20: therapeutic-use claims

Claims 14 through 20 cover treatment of ocular Demodex infestation in human patients and identify specific associated diseases:

Blepharitis
Ocular rosacea
Meibomian gland dysfunction
Ocular surface disease
Dry eye disease
Madarosis

These claims are method-of-use claims. They may be implicated where a generic or competing product carries labeling that expressly directs treatment of Demodex infestation or one of the listed conditions.

What is the strongest claim in US Patent 11,752,137?

Claim 1 is the broadest claim because it does not require a preservative, castor oil, a particular dosing frequency or a specific disease indication. It covers a sterile and nonirritating lotilaner eye drop containing approximately 0.10%-0.50% lotilaner.

Its breadth is constrained by several cumulative requirements:

Lotilaner must be present.
The product must be an ophthalmic composition in eye-drop form.
The concentration must fall within the approximate 0.10%-0.50% range.
The composition must be sterile.
The composition must be nonirritating to the eye.

Claim 1 is commercially significant because a developer cannot avoid it merely by removing hydrogenated castor oil or a preservative. Those components are not required by the independent claim.

Claim 8 is narrower but may be easier to enforce against a product that reproduces the commercial formulation. It requires the combination of approximately 0.25% lotilaner and hydrogenated castor oil.

What formulations are protected by the patent?

The patent protects several formulation configurations:

Preserved formulations

Claim 2 covers a formulation with a preservative agent. The claim does not identify a single mandatory preservative, so the scope can extend across different preservative systems if the product satisfies the other limitations of claim 1.

Preservative-free formulations

Claim 1 does not require a preservative. A preservative-free lotilaner eye drop can therefore fall within claim 1 if it otherwise satisfies the concentration, sterility, nonirritation and dosage-form limitations.

Castor-oil formulations

Claim 5 covers formulations containing castor oil. Claim 6 narrows the scope to hydrogenated castor oil. Claim 8 combines hydrogenated castor oil with approximately 0.25% lotilaner.

This structure creates a fallback hierarchy. If a formulation does not contain hydrogenated castor oil, claims 6 and 8 may not apply, but claim 1 or another broader claim could remain relevant.

Products excluding tea tree oil

Claim 4 expressly excludes tea tree oil. This negative limitation appears directed at distinguishing the claimed lotilaner formulation from conventional Demodex treatments or formulations that use tea tree oil. A product containing tea tree oil would not literally meet claim 4, although it could still fall within claim 1, depending on the remaining formulation characteristics.

Does the patent cover XDEMVY?

XDEMVY contains lotilaner at a 0.25% concentration and is administered as an ophthalmic solution. The FDA-approved regimen is one drop in each affected eye twice daily for six weeks.[1] Those characteristics correspond closely to claims 1, 7, 8, 11 and 13.

XDEMVY characteristic	Potentially corresponding claim
Lotilaner ophthalmic solution	Claim 1
0.25% lotilaner	Claims 7 and 8
Twice-daily administration	Claims 10, 11 and 13
Six-week treatment course	Claims 11 and 13
Ocular Demodex indication	Claim 14
Demodex blepharitis	Claim 15
Human patient use	Claim 14

The approved product label identifies lotilaner ophthalmic solution 0.25% for the treatment of Demodex blepharitis.[1] The label does not need to list every disease named in claims 16 through 20 for those claims to have potential relevance in a broader clinical or promotional-use analysis.

When does US Patent 11,752,137 lose exclusivity?

The patent issued on August 29, 2023. Public patent records identify a June 14, 2019 priority date for the relevant lotilaner ophthalmic subject matter. On a standard 20-year patent-term calculation, the projected expiration date is June 14, 2039, before any applicable patent-term adjustment or other term modification.[2]

Milestone	Date
Earliest identified priority date	June 14, 2019
Patent grant	August 29, 2023
Standard projected expiration	June 14, 2039
FDA approval of XDEMVY	July 25, 2023
FDA new chemical entity exclusivity	July 25, 2028

The patent term and FDA regulatory exclusivity operate independently. FDA five-year new chemical entity exclusivity for XDEMVY is scheduled to restrict submission of an ANDA or 505(b)(2) application relying on the product’s active ingredient until July 25, 2028, subject to statutory exceptions.[3]

Patent expiration could occur later than the standard calculation if patent-term adjustment applies. The precise term should be confirmed against the USPTO patent-term data for the issued patent.

What is the Orange Book status of XDEMVY?

XDEMVY was approved under NDA 217817. The product is a small-molecule prescription ophthalmic drug, not a biologic. Its generic competition would proceed through the ANDA pathway rather than through a biosimilar application.

The Orange Book is the principal FDA source for approved drug products, therapeutic-equivalence evaluations and listed patents. A patent listed for the NDA can create a certification obligation for an ANDA applicant under 21 U.S.C. § 355(j)(2)(A)(vii).[4]

Regulatory issue	XDEMVY position
Product	XDEMVY
Active ingredient	Lotilaner
Dosage form	Ophthalmic solution
Strength	0.25%
NDA	217817
Approval date	July 25, 2023
Generic pathway	ANDA
Biosimilar pathway	Not applicable
Regulatory exclusivity	Five-year NCE exclusivity, subject to statutory rules

The commercial importance of US Patent 11,752,137 depends on whether it is listed for the approved NDA and whether FDA accepts it as covering the approved product. A patent’s existence alone does not establish Orange Book listing status.

What Paragraph IV challenges could affect XDEMVY?

An ANDA applicant seeking approval before relevant patent expiry could submit a Paragraph IV certification asserting that the listed patent is invalid, unenforceable or not infringed.[4] The NDA holder would then have 45 days to bring an infringement action. A timely lawsuit can trigger a 30-month stay of FDA approval, subject to statutory exceptions and court developments.

Potential Paragraph IV strategies against this patent could target:

Concentration design-arounds

A generic developer could assess a lotilaner concentration outside the claimed 0.10%-0.50% range. This approach would face formulation, efficacy and tolerability constraints because the approved product uses 0.25% lotilaner.

Excipient design-arounds

A product could omit castor oil or hydrogenated castor oil. That would potentially avoid claims 5, 6 and 8 but would not necessarily avoid claim 1.

Dosing design-arounds

A generic product could seek labeling with a different dosing frequency or treatment duration. Such a strategy may avoid some regimen claims but could reduce alignment with the clinical data supporting the approved product.

Indication carve-outs

A generic applicant could attempt a skinny-label strategy that omits patented method-of-use indications. This would not necessarily avoid composition claims 1 through 8. It also would require careful separation of the patented Demodex uses from any nonpatented labeling.

No Paragraph IV settlement terms or court judgment concerning US Patent 11,752,137 are established by the claim text supplied here. The patent record and FDA listing must be evaluated separately from the claim language when assessing active litigation or a generic approval timetable.

Is there biosimilar risk for lotilaner?

There is no biosimilar pathway for lotilaner because lotilaner is a chemically synthesized small molecule. The relevant competitive risk is generic entry through an ANDA, potentially combined with a 505(b)(2) application for a modified ophthalmic formulation.

The principal barriers are:

FDA exclusivity through 2028.
Patent protection potentially extending to 2039.
Sterile ophthalmic manufacturing requirements.
Demonstration of product quality and preservative performance.
Bioequivalence or other FDA requirements for an ophthalmic solution.
Potential formulation and method-of-use patent assertions.
Clinical and commercial difficulty of matching a branded Demodex indication.

How strong is the patent estate?

US Patent 11,752,137 has meaningful commercial strength because it combines formulation, concentration, dosing and disease-use claims in a single patent. Its practical strength is highest against products that replicate the approved XDEMVY profile.

Estate component	Strength assessment
Core 0.10%-0.50% formulation	Broad commercial relevance
0.25% lotilaner claim	Strong alignment with XDEMVY
Hydrogenated castor oil limitation	Narrower but product-specific
Twice-daily six-week regimen	Strong alignment with approved use
Demodex treatment claims	Relevant to branded indication
Tea-tree-oil exclusion	Useful for claim differentiation, but narrower
Preservative limitation	Secondary formulation coverage

The estate is less restrictive against a product that uses a different concentration, excipient system, dosing schedule or label. The core formulation claim remains the main barrier because it does not require the narrower excipient or treatment limitations.

Validity risk would likely focus on written description and enablement for the claimed concentration range, the meaning of “nonirritating,” the scope of the negative tea-tree-oil limitation, and prior art relating to lotilaner ophthalmic delivery and Demodex treatment. The strength of those defenses depends on the specification, cited prior art and prosecution history, not on the issued claims alone.

Which companies are challenging the lotilaner patent estate?

The principal commercial participants are:

Tarsus Pharmaceuticals, associated with XDEMVY commercialization and the human ophthalmic Demodex franchise.
Elanco Animal Health, associated with lotilaner’s veterinary history and commercial use in products such as Credelio.
Potential future generic ophthalmic manufacturers, which could pursue ANDA approval after regulatory exclusivity and submit patent certifications.

Lotilaner’s veterinary use does not automatically create freedom to market a human ophthalmic product. The approved human eye-drop formulation, indication and manufacturing process raise separate regulatory and intellectual-property issues.

What licensing deals affect lotilaner?

Lotilaner originated in the veterinary pharmaceutical sector. Tarsus obtained rights to develop lotilaner for human ophthalmic use through arrangements associated with Elanco and the prior Novartis Animal Health development history.[5] The relevant commercial question is field-of-use scope: veterinary rights, human ophthalmic rights, territories, sublicensing rights, royalties and termination provisions may be allocated differently.

A license does not change the patent claims. It affects ownership, enforcement authority, royalty economics and the identity of the party able to negotiate or litigate against a generic entrant.

What generic launch scenarios exist?

Launch after patent expiry

A generic could launch after expiration of US Patent 11,752,137 and any other relevant listed patents, subject to FDA approval and remaining regulatory requirements.

Paragraph IV launch

A generic could file an ANDA with a Paragraph IV certification and proceed after litigation resolution, settlement, failure to sue within 45 days, expiration of a 30-month stay or another statutory pathway.

At-risk launch

A generic could launch before final resolution after receiving FDA approval, accepting potential damages and injunction risk. This scenario is less attractive where the branded product has a concentrated patent estate and a commercially valuable indication.

Skinny-label launch

A generic could omit patented Demodex-related uses from its labeling. This strategy would not eliminate risk from composition claims and could face inducement allegations if marketing, prescribing behavior or product design supports the patented use.

Key Takeaways

US Patent 11,752,137 is directed to sterile, nonirritating lotilaner ophthalmic drops containing approximately 0.10%-0.50% lotilaner.
The patent closely maps to XDEMVY 0.25% ophthalmic solution.
Claim 1 is the principal broad formulation claim.
Claims 8, 11 and 13 are particularly relevant to the commercial 0.25%, twice-daily, six-week regimen.
Claims 14 through 20 cover human ocular Demodex treatment and related diseases.
The standard projected patent expiration is June 14, 2039, subject to patent-term adjustment.
FDA five-year NCE exclusivity for XDEMVY runs from July 25, 2023, to July 25, 2028, subject to statutory rules.
Generic, not biosimilar, competition is the relevant future threat.
Excipient, concentration, dosing and indication design-arounds may reduce exposure to narrower claims but may not avoid claim 1.
Patent strength depends on the full specification, prosecution history, Orange Book listing status and any continuation or related patents.

FAQs

Can a lotilaner eye drop avoid US Patent 11,752,137 by omitting hydrogenated castor oil?

Possibly for claims 6 and 8, but omission would not by itself avoid claim 1, which does not require castor oil or hydrogenated castor oil.

Does a generic lotilaner product need to copy the XDEMVY 0.25% strength?

No. An ANDA applicant could pursue a different strength, but it would need to satisfy FDA requirements and assess whether the alternative concentration remains within the 0.10%-0.50% range claimed by claim 1.

Can an ANDA applicant avoid the patent by removing Demodex blepharitis from its label?

Potentially for some method-of-use claims, but composition claims would remain relevant. A label carve-out does not eliminate exposure to claims covering the product itself.

Is Credelio covered by the same human ophthalmic patent?

Credelio is a veterinary lotilaner product. The patent claims analyzed here are directed to sterile human ophthalmic eye drops and human ocular Demodex treatment, not to every lotilaner product.

Does FDA approval of XDEMVY prove that US Patent 11,752,137 is valid?

No. FDA approval and patent validity are separate issues. Approval confirms regulatory authorization of the drug product; it does not adjudicate novelty, obviousness, enablement, written description or enforceability.

References

U.S. Food and Drug Administration. (2023). XDEMVY (lotilaner ophthalmic solution) prescribing information.
United States Patent and Trademark Office. (2023). U.S. Patent No. 11,752,137, ophthalmic compositions comprising lotilaner.
U.S. Food and Drug Administration. (2023). Drugs@FDA: XDEMVY, NDA 217817.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
Elanco Animal Health Incorporated. (2023). Annual report on Form 10-K.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes	11,752,137	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018385766	⤷ Start Trial
Australia	2023200843	⤷ Start Trial
Australia	2025204628	⤷ Start Trial
Brazil	112020012018	⤷ Start Trial
Canada	3085787	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 11,752,137